Membrane-Bound TNFα (mTNFα) Lentivirus
Membrane-Bound TNFα Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. These particles result in expression of uncleavable, membrane-bound TNFα (Tumor necrosis factor alpha) driven by an EF1a promoter, and a puromycin selection marker (Figure 1).
Figure 1. Schematic of the lenti-vector used to generate Membrane-Bound TNFα (mTNFα) Lentivirus.
Name | Ordering Information |
Thaw Medium 3 | BPS Bioscience #60186 |
Lenti-Fuse™ Polybrene Viral Transduction Enhancer | BPS Bioscience #78939 |
12-well tissue culture-treated plates | |
Flow cytometer or fluorescence microscope |
The lentivirus particles were produced from HEK293T cells. They are supplied in cell culture medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations and produced at higher titers by special request, for an additional fee.
Tumor necrosis factor (TNF, also known as TNFα) is a cytokine produced predominantly by activated macrophages and T lymphocytes. It has been identified as a key regulator in inflammatory and immune responses. TNF signaling pathways are triggered by binding to one of two distinct receptors, designated TNFR1 (TNF receptor 1) and TNFR2, which are differentially regulated on various cell types in normal and diseased tissues. TNFα exists in both a trimeric membrane-bound form (mTNFα) and as a soluble protein. TNFα is synthetized in a precursor form, a cell surface type II transmembrane protein, which is cleaved by metalloproteinases such as TACE (TNFα converting enzyme) into a soluble peptide. Soluble TNFα can then bind to its receptors and activate downstream signaling pathways. Transmembrane TNFα can also bind to TNFα receptors and induce cellular responses. For instance, it can enhance cytotoxicity in NK cells, while in the liver it can trigger hepatitis. Anti-TNFα antibodies can bind to mTNFα and trigger antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) to destroy the mTNFα-expressing inflammatory cells, being a promising therapy for inflammatory diseases.
Wang F., et al., 2017 Mol Med Rep 16: 1021-1030.
Horiuchi T., et al., 2010 Rheumatology 49(7):1215-1228.